Clinical validation of real-time PCR and SNaPshot methods in comparison to NGS for KRAS and NRAS Mutation Detection in colorectal cancer at Genia Laboratories (Uruguay).

Marqués, Juan Martín; Repetto, Leticia; Guggeri, Lucia; Lamuedra, Santiago; Russo, Valentina; Torres, Alejandra; Fossati, Rosina; Azambuja, Carlos; Agorio, Astrid

doi:10.1200/jco.2015.33.15_suppl.e22121

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Future studies will need to focus on developing standardized and sensitive techniques to guide clinical decision making in selecting optimal candidates with mCRC for anti-EGFR therapy. The development of next-generation sequencing (NGS) with high-throughput functionality, which has shown comparable accuracy in detecting RAS mutations to real-time PCR, represents one increasingly popular strategy (84).…”

Section: Discussion and Future Directionsmentioning

confidence: 99%

RAS and BRAF in metastatic colorectal cancer management

Gong

Cho

Fakih

2016

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

The treatment of metastatic colorectal cancer (mCRC) has been further refined with the development of monoclonal antibodies, cetuximab and panitumumab, towards the epidermal growth factor receptor (EGFR). Anti-EGFR therapy has afforded improved survival in those with wild-type RAS mCRC but provides no benefit and even harm in those with RAS-mutant tumors. mutations have also been shown to predict lack of clinically meaningful benefit to anti-EGFR therapy in mCRC. Mechanisms of resistance to EGFR blockade in wild-type or metastatic colorectal tumors appear to converge on the mitogen-activated protein kinase (MAPK) signaling pathway. Clinical trials involving combined BRAF, EGFR, and/or MAPK kinase (MEK) inhibition have shown promising activity in-mutant mCRC. Here, we review pivotal clinical trials that have redefined our treatment approach in mCRC with respect to anti-EGFR therapy based on and mutation status. Future studies will likely focus on improving efficacy of anti-EGFR-based therapy in mCRC through sustained MAPK pathway inhibition.

show abstract

Section: Discussion and Future Directionsmentioning

confidence: 99%